REDLAMP 11: Does a Family History of Lymphoma Increase My Risk?

Great strides in the understanding of familial predisposition to common forms of lymphoma including non-Hodgkin lymphoma, Hodgkin lymphoma, and chronic lymphocytic leukemia have been made in the past decade. Many lymphoma patients wonder if their family faces an increased risk. In this video Dr. Peter Martin explains the results from a recent study published in Blood, which sought to quantify these risks, and give a better understanding of how a family history of lymphoma increases the risk for other family members.

Previous #REDLAMP entries can be viewed on our Youtube channel.

We encourage you to follow the Lymphoma Program on Twitter, Youtube, and Facebook where we will highlight new videos are about research publications as they are released. We also welcome your feedback, suggestions and questions about this project. If you have other questions about our lymphoma program or clinical trials or would like to see one of our lymphoma specialists, please contact us at 212-746-2919.

Dr. Richard Furman Discusses Emerging Strategies for the Treatment of CLL & Follicular Lymphoma

In this video from Onc Live, Dr. Richard Furman, Director of the CLL Research Center discusses emerging strategies in the treatment of CLL and follicular lymphoma, specifically citing the use of venetoclax also known as ABT-199.

For patients with CLL the following trials are open to accrual.

Dr. Richard Furman Discusses the Lessening of Infusion Reactions for CLL Patients Treated with Rituximab, Obinutuzumab, or Ofatumumab

In this video from OncLive, Director of the CLL Research Center, Richard R. Furman, M.D. discusses infusion reactions for  chronic lymphocytic leukemia (CLL) patients treated with anti-CD20 antibodies, including rituximab, obinutuzumab, and ofatumumab.